NovaBay Pharmaceuticals Культура компании

Mr. Mark M. Sieczkarek, M.B.A., serves as the Chief Executive Officer of Fe3 Medical, Inc. Mr. Sieczkarek has been the Chief Executive Officer at NovaBay Pharmaceuticals, Inc. since June 3, 2016 and has been its President since June 13, 2016. He served as an Interim Chief Executive Officer and Interim President at NovaBay Pharmaceuticals, Inc from November 28, 2015 to June 3, 2016. He served as an Interim Chief Executive Officer and Interim President of Solta Medical, Inc., from August 23, 2013 to January 24, 2014. He served as the President and Chief Executive Officer of Conceptus, Inc., from April 2003 to December 2011. He served as President of Americas, of Bausch and Lomb, Inc. from July 2001 to January 2003, as a Corporate Vice President and President of Europe, Middle East and Africa Region from 1999 to 2001 and held positions at its various divisions from 1995 to 1999. He served as a Vice President and the Chief Financial Officer of KOS Pharmaceuticals from 1993 to 1995. He has more than 18 years of leadership experience in the medical device industry. He served as a Senior Vice President of Americas Region and President of Americas Region of Bausch & Lomb Incorporated, responsible for the commercial operation of all Bausch & Lomb businesses in the United States, Canada and Latin America. He joined Bausch & Lomb in 1995 as Vice President and Controller in the Personal Products division and also served as a Vice President in Corporate Business Development. From 1980 to 1993, he held executive level positions in Finance and Commercial Operations with several Bristol Myers-Squibb subsidiaries and at Sanofi Diagnostics Pasteur. He has been the Chairman of NovaBay Pharmaceuticals, Inc. since April 2015. He served as the Chairman of Solta Medical, Inc. from June 12, 2013 to January 24, 2014. He has been a Director of NovaBay Pharmaceuticals, Inc. since January 2014. He serves as a Director of The Medical Device Manufacturers Association. He served as Lead Independent Director of Solta Medical, Inc. from January 2008 to August 06, 2013 and also served as its Director from July 2006 to January 23, 2014. He served as an Independent Director of Conceptus, Inc. from April 2003 to December 2011. He serves on the national board of Directors of Prevent Blindness America and is also on the board of St. John Fisher College. Mr. Sieczkarek holds a B.S. in Accounting from the State University of New York at Buffalo and an M.B.A. in Finance from Canisius College.

Mr. Lewis J. Stuart, BA, MBA, has been the Chief Commercial Officer at NovaBay Pharmaceuticals, Inc. since December 01, 2017. Mr. Stuart served as Vice President of Sales & Marketing - US Breast & Colon at Genomic Health Inc. Mr. Stuart has more than 30 years of global healthcare commercial experience across multiple sectors including oncology, cardiovascular and infectious disease. He served as the General Manager of US Operations at Genetic Technologies Ltd., since June 2010 and served as its General Manager of Phenogen Sciences Inc., since July 5, 2010. He served as President of Phenogen Sciences Inc., since April 16, 2011. He served as General Manager of North American Molecular Diagnostics at Genetic Technologies Ltd., since June 16, 2010. He served as Vice President, US Oncology, of Genomic Health, Inc., a biotechnological company providing genomic-based diagnostic tests that help optimize cancer care, since 2013. From 2010 to 2013, Mr. Stuart served as President and General Manager of Genetic Technologies, Inc. He served as Senior Vice President of Commercial Operations at Gilead Palo Alto, Inc., (also known as CV Therapeutics, Inc.) since July 16, 2007 and its Vice President of Sales from July 10, 2003 to July 2007. He joined Insmed Incorporated on August 19, 2002 and served as its Vice President of Commercial Development from October 30, 2002 to June 19, 2003. He was responsible for the strategic leadership and overall management of the field sales organization for Ranexa(TM) (ranolazine) and other potential CV Therapeutics products. Mr. Stuart has over 25 years experience in a variety of therapeutic categories, including endocrinology, women's health, cardiovascular, CNS and infectious diseases. He served as Vice President of U.S. National Sales and Community Marketing at Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from March 1996 to August 2002. There, he fielded an HIV sales organization to launch Agouron''s lead product, Viracept(R), which was the most widely prescribed protease inhibitor in the U.S. Prior to joining Agouron, from 1986 to 1996, he held various leadership positions at Solvay Pharmaceuticals, Centocor, Upjohn and Bristol Myers Squibb. He also directed the sales teams for several cardiovascular products at Capoten(R), an ACE inhibitor prescribed to treat high blood pressure and congestive heart failure and Corgard(R), a beta blocker prescribed to treat angina and high blood pressure. He has been a Director of Linkage Biosciences, Inc., since November 2014. Mr. Stuart graduated with a BA in Marketing Communications from Virginia Polytechnic Institute and State University in 1982.

Mr. Todd Erik Zavodnick has been Chief Commercial Officer and President of Aesthetics & Therapeutics of Revance Therapeutics, Inc. since August 1, 2017. Mr. Zavodnick served as the President of International at ZELTIQ Aesthetics, Inc. since February 2016 until April 28, 2017. Mr. Zavodnick joined ZELTIQ in February 2016. Prior to joining ZELTIQ, he served as the President and General Manager of Galderma North America. He also served as Vice President and General Manager for Galderma's USA Aesthetic & Corrective Business Unit and Senior Regional Director for Galderma's European and Latin America Operations. In his career, Mr. Zavodnick has spent time leading organizations in Asia (residing in Beijing, China, for four years), Europe (residing in Lausanne, Switzerland, for two and a half years), the Middle East, Africa and Latin America for Alcon Laboratories and Galderma Laboratories. He served as president at Alcon China and Mongolia. He began his career as a Registered Pharmacist. He serves as Director at Allurion Technologies, Inc. He has been a Director of NovaBay Pharmaceuticals, Inc. since May 6, 2016. He serves as on the Board of Directors for the Children's Skin Disease Foundations. Mr. Zavodnick received a Bachelor of Science degree in Pharmacy from Rutgers University and an MBA in International Business from University of Texas in Dallas.

Dr. David W. Stroman, Ph.D. has been Senior Vice President of Ophthalmology at NovaBay Pharmaceuticals, Inc. since October 4, 2011. Dr. Stroman has over four decades of experience in the medical products industry. Dr. Stroman has spent in the pharmaceutical industry in various aspects of antibiotic research and development as well as in the biotechnology industry. He served as Head of Ophthalmic Drug Development at NovaBay Pharmaceuticals. He served for 21 years at Alcon, as Therapeutic Unit Head for Anti-Infectives. Dr. Stroman joined Alcon in 1990 to create and lead the Anti-Infective program. In addition, beginning in 1995, he led the Clinical Microbiology group. Prior to Alcon, he served for 9 years with the Infectious Disease Research Unit of The Upjohn Company, leading Phillips Petroleum Company's biotechnology program and its joint ventures with The Salk Institute, Bissendorf Peptide, GmbH, and Baylor College of Medicine. He serves as Chair of the Ophthalmology Advisory Board at NovaBay Pharmaceuticals, Inc. and has been its Member of Ophthalmic Advisory Board since 2011. He is an inventor on more than 10 patents and has published over 25 peer-reviewed articles. He holds B.S. in chemistry from Southern Nazarene University. Dr. Stroman received his Ph.D. degree in Biochemistry and Molecular Biology from the University of Oklahoma Medical School, Oklahoma City, OK. He received his post-doctoral training at the Department of Microbiology and Immunology, Washington University School of Medicine, St. Louis, MO.

Mr. John J. McGovern, also known as Jack, has been the Chief Financial Officer, Treasurer and Principal Accounting Officer of NovaBay Pharmaceuticals, Inc. since July 2017. Mr. McGovern has more than 30 years of experience in finance and operations, primarily in the San Francisco Bay Area. He served as Chief Operating Officer and Chief Financial Officer of Attainia, Inc. since 2013 (sold to a private equity firm). He served as Managing Partner at Northshore Management Partners for eight years. He served as Chief Operating Officer/Chief Financial Officer at Integrated Biosystems. During his tenure, he was responsible for all acquisitions and dispositions for Cemex in the US and Caribbean. He joined Matrix Leasing International, an advisor to Northwest Airlines, where he financed in excess of $3 billion in aircraft acquisitions. He served as Executive Vice President at Strategic Capital, Inc., a boutique investment bank with a focus on M&A and Chief Operating Officer/Chief Financial Officer of Oliver-Allen Corp., a computer leasing company. He has served as the Chief Financial Officer and Chief Operating Officer of both public and private companies in a variety of industries providing direction on strategy, capital formation, operations and M&A activity. He served as Chief Financial Officer at Axcient, Inc. He served as Chief Financial Officer at Dilithium Inc. He served as Partner at Ashwood Management Partners, LLC in the position of Partner. He served as Chief Financial Officer at Ensenda, LLC. He began his career as an auditor at KPMG. Mr. McGovern received a BS in accounting from Chico State University and is a licensed CPA in the State of California.

Colin Scott serves as the VP Clinical Research & Development of NovaBay Pharmaceuticals. Colin currently resides in the San Francisco Bay Area.